Kova’s lowest advertised monthly price is not its one-month price, and its first charge does not follow the same rules as later charges. Those two distinctions matter more to a household budget than a single headline number. The platform advertises access to compounded semaglutide and tirzepatide through independent clinicians and pharmacies, with medication, delivery and app access bundled into a subscription. Choosing among its plans means separating the introductory offer, the selected plan duration, the payment option and the recurring billing terms.
The documents consulted on October 19, 2026, provide unusually specific prices across four plan durations, but leave an important gap: the available terms excerpt cuts off within the financial provisions, preventing a complete review of cancellation, refunds and possible multimonth obligations. This documentary review therefore distinguishes published prices from unresolved commitments. It also separates Kova’s technology business, operated by LifeTech Apps Inc, from the independent professionals responsible for clinical decisions and the pharmacies responsible for dispensing.
At a glance
- Semaglutide one-month offer
- $249 for the first month, renewing at $299 per month. Longer plans advertise different monthly or upfront payment options.Sources: [4]
- Tirzepatide one-month offer
- $299 for the first month, then renewal at $399; that specific renewal line does not repeat the billing-period unit.Sources: [4]
- Initial charge condition
- Kova may place an authorization hold, but says it captures the initial plan charge only after clinical eligibility is determined and the initial prescription is issued.Sources: [5]
- Included and separate costs
- The advertised subscription includes consultations, prescription fulfillment, medication delivery, ongoing support and app access. Required laboratory work costs extra.Sources: [4]
Start with the renewal price, not the introductory month
Kova’s one-month semaglutide plan costs $249 for the first month and then renews at $299 per month. The one-month tirzepatide plan starts at $299 and says it “renews at $399.” Because that tirzepatide sentence does not repeat a period after the renewal amount, a buyer should confirm the billing interval in the actual order rather than silently supply the missing wording. Both offers distinguish the first payment from the subsequent charge.
The longer options work differently. Semaglutide is advertised at $179 per month or $537 upfront for three months; $149 per month or $894 upfront for six months; and $129 per month or $1,548 upfront for twelve months. Tirzepatide is listed at $249 per month or $747 upfront, $229 per month or $1,374 upfront, and $199 per month or $2,388 upfront for those respective durations.
The word “or” matters: these are advertised payment alternatives, not evidence that everyone must prepay. Nor does a twelve-month plan label establish the quantity shipped, a minimum commitment or what happens after early cancellation. The table preserves the published choices without adding annualized projections. Our guide to introductory offers and renewal prices explains why the first attractive number should be read alongside the next charge.
| Plan duration | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| 1 month | $249 first month; then $299/month | $299 first month; then $399, with renewal period not repeated |
| 3 months | $179/month or $537 upfront | $249/month or $747 upfront |
| 6 months | $149/month or $894 upfront | $229/month or $1,374 upfront |
| 12 months | $129/month or $1,548 upfront | $199/month or $2,388 upfront |
The first-payment safeguard does not govern every later charge
Kova’s terms draw a useful distinction between authorizing a payment method and collecting the initial plan charge. At enrollment, the company may place a temporary authorization hold. It says it will not capture that initial charge unless a provider determines clinical eligibility and issues the first prescription. If no initial prescription is issued, the hold is released or voided. The supplied text does not establish how quickly a payment account will display that release.
After enrollment, the arrangement changes. Scheduled recurring charges may be processed before a subsequent clinical review, refill request, prescription renewal or dose change is completed. The terms expressly separate the billing cycle from reviews, prescriptions, refills and medication shipments. In practical budget terms, a successful renewal payment is not confirmation that a new prescription has already been issued or that a package has already left the pharmacy.
The terms also say that plan conditions presented at checkout or enrollment and confirmed in the order control over inconsistent economic provisions in the general financial section, except where prohibited by law. Those checkout documents were not available for this review. Before paying, obtain the selected payment schedule and the next charge date in writing; our explanation of GLP-1 billing cycles helps distinguish payment timing from treatment and shipment timing.
What the subscription includes—and what still needs a budget
Kova describes a bundled subscription covering clinician consultations, prescription fulfillment, medication delivery, ongoing care support and full access to its companion app. It explicitly says there are no separate charges for the medication itself. Another summary lists clinician review, prescription eligibility assessment, fulfillment coordination, educational resources and ongoing check-ins “where applicable.” That qualification matters: a broad support promise is not a documented schedule of visits or a guarantee of a particular follow-up frequency.
Laboratory testing is the clearly identified extra expense. If a clinician considers tests necessary, the provider can order them and review the results, but the program does not include the laboratory work. The supplied evidence contains no laboratory price schedule. A useful written quote would therefore distinguish the subscription from any potential testing expense and explain where tests would be performed and billed. Bundled medication pricing should not be mistaken for an exhaustive ceiling on every care-related cost.
Insurance is not required, and Kova says the advertised price is the same regardless of insurance status. It suggests asking an FSA or HSA administrator about reimbursement eligibility; that is not a promise that a particular account will reimburse the charge. For a practical comparison, separate what Kova expressly includes from expenses it leaves outside the subscription. The included-costs checklist offers a framework for organizing those questions without assuming an unlisted service is covered.
Cancellation is documented more clearly than repayment
Kova’s public page says a subscription can be canceled at any time, either through the account page or by contacting support. Its more specific explanation says access ends after the paid period: the active medication plan, upcoming refills, clinical care through the platform and companion app are then no longer available. Restarting may require a new clinical evaluation. Another page answer describes access ending on cancellation without the same timing detail, so written confirmation is worthwhile.
What the available record does not establish is equally important. The supplied terms excerpt stops within the financial provisions and does not permit reconstruction of the complete general cancellation and refund rules. It therefore cannot settle whether a multimonth payment option carries remaining obligations, how an unused prepaid period is handled, or what notice is needed to prevent a scheduled renewal. A public statement permitting cancellation does not, by itself, establish a refund entitlement.
Before selecting a longer plan, ask Kova to identify the applicable cancellation provision, the effective end date, any remaining charges and the treatment of unused prepaid amounts. Keep the answer with the checkout confirmation rather than relying only on a general FAQ. Our guide to cancellation and refunds explains the distinction between stopping a subscription and recovering money. Here, the missing contractual text is a material comparison limitation, not proof of either a favorable or unfavorable policy.
Who delivers the service behind the Kova price
LifeTech Apps Inc operates the KOVA technology platform, including the mobile app, website, accounts, portals and enrollment flows. Its terms say the company does not provide medical, pharmacy or laboratory services; independent medical provider groups and licensed healthcare professionals provide clinical services. The website identifies a registered office in Wilmington, Delaware. That business address identifies the platform operator, not the location of every treating professional or dispensing pharmacy.
Kova says it works with Telegra’s provider network and attributes a nationwide network of 503a and 503b compounding pharmacies to Telegra MD LLC. These are website descriptions, not independently verified licensing findings. The page names Laurie Mercier, MD, and nurse practitioners Kimberli Hastings, Theresa Vergara and Craig Sorkin. It also lists E-RxHub, Absolute Pharmacy, Southend Pharmacy, Strive Pharmacy and Pharmacy Boudreaux’s, but the available documents do not identify which pharmacy would fill an individual patient’s prescription.
Enrollment begins with a questionnaire about goals, medical history and treatment preferences, including injectable versus oral treatment. A licensed clinician reviews the intake online and determines appropriateness; Kova says nothing ships without provider approval. The questionnaire’s route question does not confirm a particular oral or injectable formulation, concentration or presentation. People already taking a GLP-1 must also complete intake so a clinician can assess possible continuation or transition rather than assuming an automatic transfer.
Delivery is included, but timing and supply remain separate questions
Although Kova includes medication delivery in its advertised subscription, its terms describe shipping and delivery dates as estimates. Clinical review, pharmacy processing, product availability and carrier operations can affect timing. The supplied documents provide no numerical timetable for these stages. They also do not establish the amount of medication in each shipment. A six- or twelve-month plan therefore should not be read as confirmation that the entire period’s supply arrives in one package.
Patients are responsible for providing an accurate address, updating it before shipment, promptly retrieving the package and storing it according to pharmacy instructions. Subject to applicable law, the terms treat a shipment as delivered when the carrier confirms delivery to that address. For an approved shipping claim, Kova may arrange a replacement at no additional charge or, when replacement is not reasonably available, provide an applicable credit or refund under the governing terms. This is a conditional remedy, not an unconditional replacement promise.
The supplied evidence also says dispensed products generally cannot be returned unless the pharmacy directs otherwise. Separately, FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That guidance is especially relevant to resolving a delivery concern; carrier confirmation alone does not answer a product-handling question. Ask which pharmacy will dispense the order and how to report a temperature or packaging problem before the first shipment.
App access and support have defined limits
Kova says every plan includes the companion app at no extra cost, with features subject to change. Advertised tools include reminders, injection-site records, symptom tracking, protein tracking, treatment history and education. The provider portal has a different practical role: secure messages to the provider, refill requests, delivery tracking and billing management. These tools are part of the advertised bundle, but their availability does not establish that a clinician continuously watches entries or responds immediately.
The website advertises the medical provider’s patient support as available 24/7, without specifying a guaranteed response time. The terms expressly disclaim continuous monitoring of health, symptoms, medication use or platform activity and say messaging, reminders and provider access do not make the platform an emergency service. For contact routing, support@trykova.com is listed for general companion-app inquiries; medication, prescription, refill and medical-care questions belong in the patient portal. Choosing the right channel matters when payment and clinical questions overlap.
Access also has geographic conditions. Platform users must be at least 18, able to enter a binding contract and located in the United States. During clinical care, they must be physically in a jurisdiction where the provider is authorized to practice. Kova advertises care and support across all 50 states, but qualifies specific services by licensure and regulations. Medication availability also depends on state, pharmacy availability and provider judgment; nationwide marketing is not confirmation of every offering everywhere.
What the price does not establish about the medication
Kova advertises access to compounded semaglutide and tirzepatide, subject to clinical evaluation and prescribing. Its terms acknowledge that compounded medications are not FDA approved, do not receive FDA premarket review for safety, effectiveness or quality, and are not FDA-approved generics. The supplied documents do not establish the exact formulation, concentration or presentation a patient would receive. Consequently, these published plan prices cannot be treated as verified quotes for a specific approved branded product or a confirmed route-specific preparation.
FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, and this review does not establish that Kova’s preparations are equivalent to approved products. FDA also reports measuring and administration errors involving compounded medicines, some associated with hospitalization. Instructions should be clarified with the prescriber or pharmacist rather than reconstructed from a price comparison or review.
For this cost assessment, clinical trial percentages would not resolve the central unknowns: what exact product is prescribed, what is supplied per shipment and what financial obligation accompanies the selected plan. Studies of approved products do not establish outcomes for Kova’s program or its compounded preparations. A meaningful final quote should connect the advertised subscription to the actual prescription and dispensing arrangement, while leaving treatment selection and individual suitability to the treating clinician.
Questions & answers
Does Kova require the full multimonth price upfront?
The public pricing presents monthly and upfront amounts as alternatives: for example, three-month semaglutide is $179 per month or $537 upfront. That wording does not establish mandatory prepayment. It also does not settle remaining obligations after cancellation. Confirm the selected payment method, duration and cancellation terms in checkout before choosing a longer plan.
Will Kova collect the first charge if no prescription is issued?
Its terms say the initial plan charge is not captured unless a provider determines clinical eligibility and issues the first prescription. Kova may place an authorization hold beforehand; if no prescription is issued, that hold is released or voided. This safeguard is specific to initial enrollment, not a promise that every later charge waits for a completed refill review.
Are medication and laboratory tests both included?
Kova says medication has no separate charge within the subscription, which also includes consultations, fulfillment, delivery, support and app access. Laboratory testing is different: if required, it is paid separately, although the clinician can order tests and review results. The available documents do not supply laboratory prices, so that potential expense remains outside the published plan comparison.
Does canceling Kova guarantee a refund for unused months?
No refund guarantee can be established from the available record. Kova permits cancellation through the account page or support and describes access ending after the paid period. However, the incomplete financial terms prevent a full assessment of unused prepaid amounts or multimonth obligations. Obtain the applicable refund provision and confirmation of any remaining charges before relying on cancellation flexibility.
Can an existing GLP-1 patient transfer directly into Kova?
Kova asks existing users to complete medical intake so a licensed provider can review current treatment and medical history. It says continuation or transition may be possible with clinical guidance, not that it is automatic. The supplied evidence does not establish specific transfer criteria, a guaranteed prescription or the exact product that would be available in a particular state.
Who should handle a refill problem or a delivery concern?
Kova directs medication, prescription, refill and medical-care questions to the patient portal, which also supports delivery tracking and billing management. Its general email is intended for companion-app inquiries. For an injectable delivery that is warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy. Kova’s advertised 24/7 support does not specify an immediate response guarantee.
Our assessment
Kova offers a comparatively detailed public price menu and clearly identifies medication, delivery, consultations and app access as bundled costs, with laboratory work separate. Its initial-charge condition is also specific: collection follows clinical eligibility and an initial prescription. The weaker point is the financial picture after enrollment. Recurring payments can precede later reviews or refills, and the incomplete terms prevent a reliable conclusion about multimonth cancellation obligations or refunds. The published monthly alternatives deserve consideration as alternatives—not mandatory upfront bills—but they are not enough to establish flexibility on exit. Before enrolling, obtain the complete plan terms, renewal schedule, cancellation and refund provisions, exact prescribed preparation and expected shipment quantity in writing. That documentation, rather than the lowest displayed monthly figure, is the sound basis for comparing Kova’s cost.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.